4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Friday

4D Molecular Therapeutics (NASDAQ:FDMT) is expected to be issuing its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.53) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

4D Molecular Therapeutics Price Performance

FDMT opened at $9.17 on Friday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34. The company has a market capitalization of $523.88 million, a P/E ratio of -2.45 and a beta of 3.01. The stock’s fifty day moving average is $8.51 and its two-hundred day moving average is $8.73.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently made changes to their positions in the stock. Martingale Asset Management L P boosted its position in 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the period. Commonwealth Equity Services LLC bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at about $150,000. Brevan Howard Capital Management LP acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $143,000. ADAR1 Capital Management LLC purchased a new stake in 4D Molecular Therapeutics during the third quarter valued at about $145,000. Finally, Bridgeway Capital Management LLC increased its holdings in shares of 4D Molecular Therapeutics by 100.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company’s stock valued at $93,000 after purchasing an additional 12,516 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on FDMT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Barclays started coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target on the stock. Finally, Leerink Partners restated an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.